ArticleAmerican journal of clinical and experimental immunology2026
Immune-metabolic crosstalk in rheumatoid arthritis: mediation effects of plasma metabolites on inflammatory cytokines.
Article in American journal of clinical and experimental immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is a chronic inflammatory condition defined by synovitis and progressive joint damage. The connection between inflammatory cytokines, molecules, and RA is still poorly understood despite the information combining both immune dysregulation and metabolic reprogramming to its pathophysiology.
methodsA two-sample Mendelian randomization (MR) analysis was carried out using summary statistics from the largest-scale genome-wide association study (GWAS) to examine the link between 91 inflammatory cytokines and RA risk. Metabolite pathways were identified through mediation analysis. Multiple MR Methods including inverse variance weighting (IVW) were used for causal estimation and the hypothesis was verified by sensitivity analysis.
resultsThe analysis results showed that there was a causal association between six inflammatory cytokines and RA. Among them, HGF and IL-10RA increased the risk of RA, while CXCL9, EN-RAGE, IFN-γ and CCL8 showed protective effects. These associations were validated using multiple MR methodologies, including inverse-variance weighting, MR-Egger regression, and leave-one-out sensitivity analyses. Further mediation MR analysis revealed seven metabolite-mediated pathways of inflammatory cytokines and RA. Specifically, the protective effect of CXCL9 was achieved in part by reducing plasma eicosapentaenoic acid (EPA; 20:5n3) levels (mediating effect = -0.007; proportion mediated = 8.10%). The protective effect of EN-RAGE was mediated by a decrease in the level of salicyluric glucuronide (mediating effect = -0.015; 12.70%). IFN-γ reduced the risk of RA through two independent metabolic pathways: reducing the level of 1-arachidonoyl-glycerol-3-phosphocholine (20:4n6) levels (mediating effect = -0.005; 4.67%), and increasing the ratio of glycine-to-pyridoxal (mediating effect = -0.020; 19.60%). In contrast, IL-10RA increases the risk of RA by increasing 3,7-dimethylurate (mediating effect = 0.011; 12.50%) and decreasing N, N-dimethylalanine levels (mediating effect = 0.010; 11.70%). The protective effect of CCL8 was mediated by the reduction of specific sphingomyelin species (d17:2/16:0, d18:2/15:0) (mediating effect = -0.012; 12.30%).
conclusionsThe results of this study not only confirmed the causal role of specific inflammatory cytokines in the pathogenesis of RA from a genetic perspective, but more importantly, for the first time, systematically revealed the specific plasma metabolite mediating pathways that connect these inflammatory cytokines to RA. These findings more specifically link the immune dysregulation of RA to metabolic remodeling, especially the protective role of IFN-γ through glycine/pyridoxal balance, and the pathway of IL-10RA through purine metabolites to affect risk, providing novel and mechanistic insights into the immunometabolic network of RA. We believe that these specific intermediate metabolites are expected to be potential candidate targets for future targeted therapies or intervention strategies, aiming to precisely regulate the interaction between inflammation and metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.